Want to see CADL full AI Analyst Report?
Top Page
Candel Therapeutics
(NASDAQ:CADL)
Select Model
Select Model
Rating:55Neutral
Price Target:
$13.00
▼(-2.11% Downside)
Action:Reiterated
Date:09/10/26
The score is held back primarily by weak financial performance typical of a pre-commercial biotech—no revenue, widening losses, and accelerating negative free cash flow—despite a reasonably supportive equity base. Offsetting factors include improving technical trends (price above key moving averages with positive MACD) and positive corporate updates tied to clinical progress and commercialization/financing preparations.
Positive Factors
Clinical validation
Achieving the primary endpoint in a 745-patient phase 3 study provides meaningful clinical validation for aglatimagene besadenovec. This milestone can support regulatory discussions, commercialization planning, and potential adoption while reducing some development uncertainty over the next several quarters.
Negative Factors
No recurring revenue
With no recurring product revenue, Candel remains dependent on financing and other non-product sources while it develops its therapies. The absence of commercial sales means operating costs cannot yet be funded internally, leaving progress and liquidity closely tied to clinical and regulatory execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical validation
Achieving the primary endpoint in a 745-patient phase 3 study provides meaningful clinical validation for aglatimagene besadenovec. This milestone can support regulatory discussions, commercialization planning, and potential adoption while reducing some development uncertainty over the next several quarters.
Read all positive factors
Candel Therapeutics (CADL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$977.91M
Dividend YieldN/A
Average Volume (3M)1.20M
Price to Earnings (P/E)―
Beta (1Y)1.23
Revenue GrowthN/A
EPS Growth-108.75%
CountryUS
Employees55
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.41
Shares Outstanding76,518,560
10 Day Avg. Volume950,120
30 Day Avg. Volume1,198,654
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)5.76
Price to Sales (P/S)0.00
P/FCF Ratio-7.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.67Price Target Upside55.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.16
Revenue Forecast (FY)N/A
Candel Therapeutics Business Overview & Revenue Model
Company Description
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical t...
How the Company Makes Money
As a clinical-stage biotechnology company, Candel Therapeutics does not have product sales from commercialized therapies; therefore, its revenue (if any) is primarily derived from non-product sources such as collaboration/license arrangements and ...
Candel Therapeutics Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
52
Neutral
Cash Flow
23
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 125.00K | 125.00K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 125.00K | 125.00K |
| EBITDA | -82.99M | -35.22M | -52.10M | -34.38M | -16.31M | -36.12M |
| Net Income | -88.53M | -38.18M | -55.18M | -37.94M | -18.79M | -36.12M |
Balance Sheet | ||||||
| Total Assets | 208.15M | 125.19M | 106.87M | 41.20M | 78.52M | 89.20M |
| Cash, Cash Equivalents and Short-Term Investments | 201.56M | 119.73M | 102.65M | 35.41M | 70.06M | 82.64M |
| Total Debt | 49.52M | 1.90M | 13.47M | 22.76M | 22.80M | 560.00K |
| Total Liabilities | 82.02M | 73.27M | 40.54M | 28.46M | 30.80M | 25.07M |
| Stockholders Equity | 126.13M | 51.92M | 66.33M | 12.74M | 47.71M | 64.14M |
Cash Flow | ||||||
| Free Cash Flow | -57.32M | -38.90M | -27.04M | -34.70M | -32.72M | -24.05M |
| Operating Cash Flow | -56.02M | -38.31M | -27.02M | -34.24M | -31.42M | -22.22M |
| Investing Cash Flow | -1.27M | -560.00K | -16.00K | -280.00K | -1.30M | -1.83M |
| Financing Cash Flow | 158.32M | 56.10M | 94.28M | -121.00K | 19.97M | 71.80M |
Candel Therapeutics Technical Analysis
Positive
13.28
Price Trends
11.03
Positive
9.49
Positive
7.43
Positive
Market Momentum
0.62
Positive
54.85
Neutral
25.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CADL, the sentiment is Positive. The current price of 13.28 is above the 20-day moving average (MA) of 12.60, above the 50-day MA of 11.03, and above the 200-day MA of 7.43, indicating a neutral trend. The MACD of 0.62 indicates Positive momentum. The RSI at 54.85 is Neutral, neither overbought nor oversold. The STOCH value of 25.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CADL.
Candel Therapeutics Risk Analysis
Candel Therapeutics disclosed 92 risk factors in its most recent earnings report. Candel Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Candel Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $1.42B | -4.69 | -159.32% | ― | ― | 2.95% | |
55 Neutral | $977.91M | -8.94 | -89.38% | ― | ― | -108.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $547.08M | -3.29 | -53.86% | ― | ― | -7.24% | |
49 Neutral | $808.41M | -8.11 | -38.46% | ― | -87.03% | -179.91% | |
45 Neutral | $1.43B | -5.10 | -47.04% | ― | -65.40% | -164.71% | |
43 Neutral | $352.14M | -0.85 | -91.62% | ― | -55.00% | 51.58% |
* Healthcare Sector Average
CADL
Candel Therapeutics
12.17
7.32
150.93%
CTMX
CytomX Therapeutics
3.54
1.47
71.01%
REPL
Replimune Group
14.45
8.46
141.24%
IMTX
Immatics
9.11
3.30
56.80%
LYEL
Lyell Immunopharma
12.88
-0.19
-1.45%
ARTV
Artiva Biotherapeutics, Inc.
10.79
8.09
299.63%
Candel Therapeutics Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Candel Therapeutics Highlights Progress of Lead Oncology Candidate
Positive
Sep 9, 2026
In September 2026, Candel Therapeutics detailed clinical progress and corporate positioning in an investor presentation highlighting its lead asset aglatimagene besadenovec. The therapy has delivered positive results across randomized phase 3 and ...
Executive/Board ChangesShareholder Meetings
Candel Therapeutics Stockholders Approve Directors and Auditor
Positive
Jun 24, 2026
Candel Therapeutics, Inc. held its Annual Meeting of Stockholders on June 23, 2026, with 73,270,239 shares of voting common stock eligible as of the April 24, 2026 record date. Shareholders voted on the election of four Class II directors and the ...
Executive/Board Changes
Candel Therapeutics Updates Employment Agreement with Chief Financial Officer
Neutral
Jun 16, 2026
On June 12, 2026, Candel Therapeutics entered into a new employment agreement with Chief Financial Officer Charles Schoch, formalizing the terms of his ongoing at-will employment. The contract maintains his annual base salary at $468,600, preserve...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.